CorMedix Shares Surge 17% as Q2 Revenue Tops $100 Million, EBITDA Outlook Raised — BigGo Finance
CorMedix Inc. shares rose 17% after Q2 2026 results. The company reported revenue of $101.9M, nearly tripling from $39.7M a year earlier, and raised full-year adjusted EBITDA guidance to $125M to $140M. DefenCath revenue was $66.1M. CorMedix plans a Q3 2026 FDA filing for Rezzayo sNDA.
How this was made
The 30-second read
Why it matters
Q2 results nearly tripled year over year, cash and operating cash flow were strong, and management raised full-year adjusted EBITDA guidance. The company also reiterated plans for a Q3 Rezzayo supplemental NDA submission and cited progress in dialysis contracting and Medicare Advantage.
Market read
Traders can act on a same-day earnings and guidance catalyst: raised EBITDA range, strong Q2 revenue/EBITDA, and a defined near-term regulatory filing timeline.
What to watch
DefenCath growth depends on dialysis provider coverage and pricing/volume visibility through 2027; any reimbursement or contracting friction could offset the raised EBITDA outlook.
Background
CorMedix is a specialty biopharma focused on dialysis infection prevention (DefenCath) and antifungal prophylaxis (Rezzayo).
Ticker impact
CorMedix reported Q2 revenue of $101.9M and raised full-year adjusted EBITDA to $125M-$140M, driving a 17% share surge.
Bullish bias for the next several sessions as traders reprice FY EBITDA and cash-flow durability; volatility likely around FDA submission/acceptance headlines.
The article discloses multiple fresh, decision-relevant datapoints: Q2 revenue/EBITDA beats, raised FY EBITDA range, and a planned Q3 Rezzayo sNDA submission with potential FDA decision in 1H 2027.
Market effects
Strength in a dialysis infection catheter franchise and antifungal prophylaxis pipeline may improve sentiment toward small-cap specialty biopharma with near-term regulatory catalysts.
Limited, primarily impacts US small-cap biotech sentiment rather than broad regional flows.
Low; the catalysts are company-specific (FDA filing timing, guidance, and US patent dispute).
Counterpoint
The stock’s move may be front-running optimism; the biggest remaining catalyst is FDA acceptance and timing for Rezzayo, which can slip and compress the multiple.
Key entities
- companyCorMedix Inc.
Reported Q2 revenue of $101.9M, raised FY adjusted EBITDA outlook to $125M-$140M, and outlined Q3 Rezzayo sNDA submission plans.
- productRezzayo
Planned supplemental NDA submission in Q3 for expanded prophylaxis indication, with potential FDA decision in 1H 2027.
- productDefenCath
Catheter lock solution; Q2 sales were $66.1M, with expanded dialysis provider coverage and pilot expansion expected in Q3 2026.
- acquired portfolioMelinta Therapeutics
Contributed $35.8M of Q2 revenue; also involved in a patent dispute where an appeals court upheld infringement findings.
- companyNexus Pharmaceuticals
Appeals court upheld a ruling barring its proposed generic antibiotic sales until patent expiry.
